valrubicin + cisplatin

VS-101 + cisplatin is a combination therapy consisting of valrubicin (VS-101) and the platinum-based chemotherapeutic agent cisplatin. Valrubicin is a semi-synthetic analog of the anthrocycline doxorubicin, which acts primarily as a DNA intercalator and an inhibitor of topoisomerase II, leading to DNA strand breaks and apoptosis. Unlike doxorubicin, valrubicin is highly lipophilic, which facilitates its uptake into tumor cells and potentially reduces systemic toxicity when administered locally. Cisplatin is a well-established antineoplastic agent that forms intra-strand and inter-strand DNA cross-links, interfering with DNA replication and transcription. The combination of these two agents is typically explored for synergistic effects in treating various malignancies, particularly in the context of bladder cancer or other solid tumors where local or systemic administration of these agents is indicated.

Other names

valrubicincisplatinVS-101 + cisplatin